AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations - PubMed (original) (raw)
. 2009 Dec 17;114(26):5352-61.
doi: 10.1182/blood-2009-05-223784. Epub 2009 Oct 6.
Hsin-An Hou, Chien-Yuan Chen, Chieh-Yu Liu, Wen-Chien Chou, Mei-Hsuan Tseng, Chi-Fei Huang, Fen-Yu Lee, Ming-Chih Liu, Ming Yao, Shang-Yi Huang, Bor-Sheng Ko, Szu-Chun Hsu, Shang-Ju Wu, Woei Tsay, Yao-Chang Chen, Liang-In Lin, Hwei-Fang Tien
Affiliations
- PMID: 19808697
- DOI: 10.1182/blood-2009-05-223784
Free article
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Jih-Luh Tang et al. Blood. 2009.
Free article
Abstract
Somatic mutation of the AML1/RUNX1(RUNX1) gene is seen in acute myeloid leukemia (AML) M0 subtype and in AML transformed from myelodysplastic syndrome, but the impact of this gene mutation on survival in AML patients remains unclear. In this study, we sought to determine the clinical implications of RUNX1 mutations in 470 adult patients with de novo non-M3 AML. Sixty-three distinct RUNX1 mutations were identified in 62 persons (13.2%); 32 were in N-terminal and 31, C-terminal. The RUNX1 mutation was closely associated with male sex, older age, lower lactic dehydrogenase value, French-American-British M0/M1 subtypes, and expression of HLA-DR and CD34, but inversely correlated with CD33, CD15, CD19, and CD56 expression. Furthermore, the mutation was positively associated with MLL/PTD but negatively associated with CEBPA and NPM1 mutations. AML patients with RUNX1 mutations had a significantly lower complete remission rate and shorter disease-free and overall survival than those without the mutation. Multivariate analysis demonstrated that RUNX1 mutation was an independent poor prognostic factor for overall survival. Sequential analysis in 133 patients revealed that none acquired novel RUNX1 mutations during clinical courses. Our findings provide evidence that RUNX1 mutations are associated with distinct biologic and clinical characteristics and poor prognosis in patients with de novo AML.
Similar articles
- RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Mendler JH, et al. J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753902 Free PMC article. Clinical Trial. - RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf IG, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K. Gaidzik VI, et al. J Clin Oncol. 2011 Apr 1;29(10):1364-72. doi: 10.1200/JCO.2010.30.7926. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343560 Clinical Trial. - RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. Greif PA, et al. Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689681 Free PMC article. - Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis.
Jalili M, Yaghmaie M, Ahmadvand M, Alimoghaddam K, Mousavi SA, Vaezi M, Ghavamzadeh A. Jalili M, et al. Asian Pac J Cancer Prev. 2018 Feb 26;19(2):325-329. doi: 10.22034/APJCP.2018.19.2.325. Asian Pac J Cancer Prev. 2018. PMID: 29479958 Free PMC article. Review. - Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y, Harada H. Harada Y, et al. J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. J Cell Physiol. 2009. PMID: 19334039 Review.
Cited by
- Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics.
Santoro N, Salutari P, Di Ianni M, Marra A. Santoro N, et al. Int J Mol Sci. 2024 Apr 11;25(8):4259. doi: 10.3390/ijms25084259. Int J Mol Sci. 2024. PMID: 38673842 Free PMC article. Review. - Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP, Fiskus WC, DiNardo CD, Reville P, Davis JA, Birdwell CE, Das K, Hou H, Takahashi K, Flores L, Ruan X, Su X, Loghavi S, Khoury JD, Bhalla KN. Mill CP, et al. Blood Cancer J. 2024 Feb 5;14(1):25. doi: 10.1038/s41408-024-00981-4. Blood Cancer J. 2024. PMID: 38316746 Free PMC article. - Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice.
Ahmad MH, Hegde M, Wong WJ, Mohammadhosseini M, Garrett L, Carrascoso A, Issac N, Ebert B, Silva JC, Pihan G, Zhu LJ, Wolfe SA, Agarwal A, Liu PP, Castilla LH. Ahmad MH, et al. Blood Adv. 2023 Dec 12;7(23):7304-7318. doi: 10.1182/bloodadvances.2023010398. Blood Adv. 2023. PMID: 37756546 Free PMC article. - Presence but not number of secondary type mutations influences outcome in de novo AML without MDS-associated or recurring cytogenetic abnormalities.
Weinberg OK, Cantu MD, Gagan J, Madanat YF, Arber DA, Hasserjian RP. Weinberg OK, et al. EJHaem. 2023 May 18;4(3):760-764. doi: 10.1002/jha2.710. eCollection 2023 Aug. EJHaem. 2023. PMID: 37601841 Free PMC article. - Insights into the New Molecular Updates in Acute Myeloid Leukemia Pathogenesis.
Demir D. Demir D. Genes (Basel). 2023 Jul 10;14(7):1424. doi: 10.3390/genes14071424. Genes (Basel). 2023. PMID: 37510328 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials